Anthim
Elusys has been awarded over $450 million in procurement and development contracts and has been able to advance ANTHIM to the commercial stage
elusys.comCrawled Nov 20, 2026
Elusys has been awarded over $450 million in procurement and development contracts and has been able to advance ANTHIM to the commercial stage
The page describes how anthrax functions and the health risks it presents.
The company outlines its pipeline and programs focused on neutralizing inhalational anthrax.
Publications from Elusys Therapeutics
Live Attenuated Single-Dose Spore-Based MDR-Anthrax Vaccine elicits protective immunity for postexposure Anthrax prophylaxis
Urges Swift Passage of H.R. 2707, the First Standalone Anthrax Preparedness Legislation in Over a Decade
The page provides news and media coverage, including breaking stories, analysis, and expert opinions.
Elusys Therapeutics announced the European Commission approved obiltoxaximab, its anthrax antitoxin, for treating and preventing inhalational anthrax in all age groups.
European Commission Decision Anticipated in November 2020
Decades of experience in the infectious disease space, the Elusys team spans drug development, regulatory, clinical, manufacturing, business development, and government affairs expertise.
Andy Weber is a Former Assistant Secretary of Defense and a member of the Elusys Therapeutics team.
Annie Chester is a Manager of Government Affairs and a member of the Elusys Therapeutics team.
David F. Lasseter is a Former Deputy Assistant Secretary of Defense and a member of the Elusys Therapeutics team.
Dr. Gregory Koblentz is a Biodefense Professor, George Mason University and a member of the Elusys Therapeutics team.
Mark Pryor is a Former US Senator and a member of the Elusys Therapeutics team.
About Elusys Therapeutics who develops medical countermeasures against bioterrorism and high-consequence biological threats.
Stockpiled Defenses for the Deadliest Biological Threats
The privacy policy explains what data elusys.com collects, why it is collected, and user rights related to it.